Labcorp Q3 Earnings Soar 54% on Robust Revenue Growth

TL;DR

**Labcorp's Q3 numbers are a shot in the arm, showing strong growth and smart capital deployment despite a cash dip; buy the dip if you believe in healthcare's long game.**

AI Summary

Labcorp Holdings Inc. (LH) reported a strong financial performance for the three and nine months ended September 30, 2025. Revenues increased by 8.5% to $3,563.5 million for the three months ended September 30, 2025, up from $3,282.0 million in the prior year period. Net earnings attributable to Labcorp Holdings Inc. surged by 54.2% to $261.1 million for the quarter, compared to $169.3 million in the same period of 2024. For the nine months, revenues grew by 7.8% to $10,435.9 million, and net earnings attributable to Labcorp increased by 18.1% to $711.8 million. The company's Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS) segments consistently contributed approximately 78% and 22% of revenues, respectively. Cash and cash equivalents decreased significantly from $1,518.7 million at December 31, 2024, to $598.1 million at September 30, 2025, primarily due to $324.0 million in business acquisitions and $225.0 million in common stock repurchases during the nine-month period. The company also accelerated the realization of $194.7 million in deferred tax assets due to the One Big Beautiful Bill Act.

Why It Matters

Labcorp's strong performance, particularly the 54.2% jump in net earnings, signals robust demand for its diagnostic and biopharma services, which could attract more investor interest in the healthcare sector. For employees, continued growth and strategic acquisitions, like the $324.0 million spent on new businesses, suggest job stability and potential expansion opportunities. Customers benefit from Labcorp's expanded capabilities and continued investment in its core services, reinforcing its competitive position against rivals like Quest Diagnostics. The broader market sees a healthy indicator of healthcare spending and innovation, especially with the acceleration of deferred tax assets from the OBBBA, potentially freeing up capital for further investment.

Risk Assessment

Risk Level: medium — The company's cash and cash equivalents decreased significantly by $920.6 million during the nine months ended September 30, 2025, from $1,518.7 million to $598.1 million. This substantial reduction, driven by acquisitions and share repurchases, could limit short-term liquidity for unforeseen operational needs or future strategic investments, despite strong operating cash flow of $1,026.3 million.

Analyst Insight

Investors should consider Labcorp's strong earnings growth and strategic acquisitions as positive long-term indicators. However, monitor the significant reduction in cash and cash equivalents, and assess if the company's debt management and future cash generation can sustain its growth strategy without undue liquidity strain.

Financial Highlights

debt To Equity

1.09

revenue

$3,563.5M

operating Margin

11.1%

total Assets

$18,261.6M

total Debt

$5,582.4M

net Income

$261.1M

eps

N/A

gross Margin

28.8%

cash Position

$598.1M

revenue Growth

+8.5%

Revenue Breakdown

Key Numbers

• $3,563.5M — Revenues (Increased 8.5% for the three months ended September 30, 2025, from $3,282.0M in 2024.)
• $261.1M — Net Earnings Attributable to Labcorp (Increased 54.2% for the three months ended September 30, 2025, from $169.3M in 2024.)
• $10,435.9M — Revenues (Nine Months) (Increased 7.8% for the nine months ended September 30, 2025, from $9,679.5M in 2024.)
• $711.8M — Net Earnings Attributable to Labcorp (Nine Months) (Increased 18.1% for the nine months ended September 30, 2025, from $602.6M in 2024.)
• $598.1M — Cash and Cash Equivalents (Decreased from $1,518.7M at December 31, 2024, representing a $920.6M decrease.)
• $324.0M — Cash Paid for Acquisitions (Used for business acquisitions during the nine months ended September 30, 2025.)
• $225.0M — Purchase of Common Stock (Amount spent on share repurchases during the nine months ended September 30, 2025.)
• $194.7M — Deferred Tax Assets Realization (Accelerated due to the One Big Beautiful Bill Act.)
• 82.9M — Shares Outstanding (As of October 30, 2025, down from 83.4M at December 31, 2024.)
• $1,026.3M — Net Cash Provided by Operating Activities (For the nine months ended September 30, 2025, up from $808.6M in 2024.)

Key Players & Entities

• LABCORP HOLDINGS INC. (company) — registrant
• New York Stock Exchange (regulator) — exchange for common stock
• Diagnostics Laboratories (company) — segment contributing 78% of revenues
• Biopharma Laboratory Services (company) — segment contributing 22% of revenues
• Financial Accounting Standards Board (regulator) — issued accounting pronouncements
• One Big Beautiful Bill Act (regulator) — U.S. government act impacting deferred tax assets
• BioReference Health (company) — acquired business
• $3,563.5 (dollar_amount) — revenues for three months ended September 30, 2025
• $261.1 (dollar_amount) — net earnings attributable to Labcorp for three months ended September 30, 2025
• $194.7 (dollar_amount) — accelerated deferred tax assets

FAQ

Risk Factors

• Integration of Acquisitions [medium — operational]: The company has made significant investments in business acquisitions, spending $324.0 million in the nine months ended September 30, 2025. Successful integration of these acquired businesses is critical for realizing expected synergies and growth, and failure to do so could negatively impact financial performance.
• Share Repurchases and Cash Position [medium — financial]: Labcorp repurchased $225.0 million of common stock and saw a significant decrease in cash and cash equivalents from $1,518.7 million to $598.1 million. While this can enhance shareholder value, it reduces liquidity and may limit the company's flexibility for future investments or unexpected needs.
• Tax Law Changes [low — regulatory]: The company accelerated the realization of $194.7 million in deferred tax assets due to the 'One Big Beautiful Bill Act'. While this provided a near-term benefit, changes in tax legislation can introduce ongoing complexities and potential future impacts on profitability.
• Competition in Diagnostics and Biopharma [medium — market]: The Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS) segments, representing 78% and 22% of revenues respectively, operate in competitive markets. Maintaining market share and pricing power against competitors is essential for sustained revenue growth.

Industry Context

Labcorp operates in the highly competitive healthcare diagnostics and biopharma services sectors. The industry is characterized by ongoing technological advancements, increasing demand for specialized testing, and a trend towards outsourcing by pharmaceutical companies. Consolidation through mergers and acquisitions is also a common strategy to gain scale and market share.

Regulatory Implications

Changes in tax legislation, such as the 'One Big Beautiful Bill Act,' can significantly impact a company's financial reporting and tax liabilities, as seen with Labcorp's accelerated realization of deferred tax assets. Compliance with healthcare regulations and data privacy laws remains a constant challenge and potential risk.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-09-30: End of Third Quarter 2025 — Reported strong revenue growth of 8.5% and a significant increase in net earnings of 54.2% for the quarter.
• 2025-09-30: End of Nine Months 2025 — Achieved revenue growth of 7.8% and net earnings increase of 18.1%, demonstrating consistent performance over the year.
• 2025-09-30: Cash and Cash Equivalents Balance — Decreased to $598.1M from $1,518.7M at year-end 2024, reflecting significant cash deployment for acquisitions and share repurchases.
• 2025-09-30: Common Stock Outstanding — Reduced to 82.9M shares from 83.4M at year-end 2024, indicating ongoing share repurchase activity.

Glossary

Deferred Tax Assets

Assets that result from temporary differences between accounting income and taxable income, or from tax loss and credit carryforwards. They can reduce future tax payments. (The company accelerated the realization of $194.7M in these assets, impacting current tax provisions and net earnings.)

Goodwill

An intangible asset that arises when one company acquires another for a price greater than the fair market value of its identifiable net assets. (Goodwill increased to $6,682.3M, indicating significant acquisitions or revaluations, and is subject to impairment testing.)

Noncontrolling Interest

The portion of equity in a subsidiary that is not attributable to the parent company. It represents the ownership stake of outside shareholders. (This is a deduction from net earnings to arrive at net earnings attributable to Labcorp Holdings Inc.)

Operating Income

A measure of a company's profit after deducting operating expenses from its revenue. It reflects the profitability of core business operations. (Operating income increased significantly to $396.6M for the quarter, showing improved operational efficiency.)

Year-Over-Year Comparison

Labcorp Holdings Inc. has demonstrated robust year-over-year performance. For the three months ended September 30, 2025, revenues grew by 8.5% and net earnings surged by 54.2% compared to the prior year. This positive trend continued for the nine-month period, with revenues up 7.8% and net earnings increasing by 18.1%. The company's operating income also saw a substantial increase, indicating improved profitability. However, cash and cash equivalents have significantly decreased due to strategic investments in acquisitions and share repurchases, while total liabilities have decreased, suggesting a strengthening balance sheet in terms of leverage.

Key Financial Figures

• $0.10 — ange on which registered Common Stock, $0.10 par value LH New York Stock Exchange

Filing Documents

• lh-20250930.htm (10-Q) — 1463KB
• ex221q32025.htm (EX-22.1) — 5KB
• ex311q32025.htm (EX-31.1) — 10KB
• ex312q32025.htm (EX-31.2) — 10KB
• ex32q32025.htm (EX-32) — 9KB
• 0000920148-25-000096.txt ( ) — 8275KB
• lh-20250930.xsd (EX-101.SCH) — 46KB
• lh-20250930_cal.xml (EX-101.CAL) — 57KB
• lh-20250930_def.xml (EX-101.DEF) — 330KB
• lh-20250930_lab.xml (EX-101.LAB) — 660KB
• lh-20250930_pre.xml (EX-101.PRE) — 486KB
• lh-20250930_htm.xml (XML) — 1443KB

Financial Information

Part I. Financial Information Page

Financial Statements

Item 1. Financial Statements Condensed Consolidated Balance Sheets (Unaudited) 2 Condensed Consolidated Statements of Operations (Unaudited) 3 Condensed Consolidated Statements of Comprehensive Earnings (Unaudited) 4 Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) 5 Condensed Consolidated Statements of Cash Flows (Unaudited) 6 Notes to the Condensed Consolidated Financial Statements (Unaudited) 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 22

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 32

Controls and Procedures

Item 4. Controls and Procedures 33

Other Information

Part II. Other Information

Legal Proceedings

Item 1. Legal Proceedings 34

Risk Factors

Item 1A. Risk Factors 34

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 3. Defaults Upon Senior Securities 34 Item 4. Mine Safety Disclosures 34

Other Information

Item 5. Other Information 34

Exhibits

Item 6. Exhibits 35

Signatures

Signatures 36 1 TABLE OF CONTENTS

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS LABCORP HOLDINGS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In Millions) (Unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 598.1 $ 1,518.7 Accounts receivable, net 2,109.1 1,944.1 Unbilled services, net 156.1 152.9 Supplies inventory 521.5 493.2 Prepaid expenses and other 694.0 697.6 Total current assets 4,078.8 4,806.5 Property, plant, and equipment, net 3,112.8 3,045.4 Goodwill, net 6,682.3 6,369.7 Intangible assets, net 3,571.4 3,488.9 Joint venture partnerships and equity method investments 168.2 16.3 Other assets, net 648.1 652.2 Total assets $ 18,261.6 $ 18,379.0 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 668.5 $ 875.8 Accrued expenses and other 878.0 871.2 Unearned revenue 391.6 392.2 Short-term operating lease liabilities 186.7 184.6 Short-term finance lease liabilities 4.5 6.1 Short-term borrowings and current portion of long-term debt 499.9 1,000.3 Total current liabilities 2,629.2 3,330.2 Long-term debt 5,082.5 5,331.2 Operating lease liabilities 692.0 676.3 Financing lease liabilities 64.3 74.3 Deferred income taxes and other tax liabilities 441.5 383.1 Other liabilities 639.1 517.4 Total liabilities 9,548.6 10,312.5 Commitments and contingent liabilities Noncontrolling interest 16.1 14.3 Shareholders' equity: Common stock 83.0 and 83.4 shares outstanding at September 30, 2025, and December 31, 2024, respectively 7.5 7.6 Additional paid-in capital 33.0 2.8 Retained earnings 8,698.4 8,303.4 Accumulated other comprehensive loss ( 42.0 ) ( 261.6 ) Total shareholders' equity 8,696.9 8,052.2 Total liabilities and shareholders' equity $ 18,261.6 $ 18,379.0 The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements. 2 TABLE OF CONTENTS LABCORP HOLDINGS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In